期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 153, 期 6, 页码 753-757出版社
WILEY
DOI: 10.1111/j.1365-2141.2011.08662.x
关键词
AML prognostic marker; MLLT11; MLL fusion gene; MIR29; AML survival
类别
资金
- ASCO
- The John Hartford Foundation
- Association of Specialty Professors
P>MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P < 0 center dot 05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P = 0 center dot 038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据